Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next generation sequencing facilities quantitative analysis of SHARPIN knockout or non-target LoVo cells

ABSTRACT: Next generation sequencing facilities quantitative analysis of SHARPIN knockout or non-target LoVo cells

PROVIDER: PRJNA1074367 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27906481_1.fastq.gz	Fastqsanger.gz
	SRR27906481_2.fastq.gz	Fastqsanger.gz
	SRR27906482_1.fastq.gz	Fastqsanger.gz
	SRR27906482_2.fastq.gz	Fastqsanger.gz
	SRR27906483_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Next generation sequencing facilities quantitative analysis of SHARPIN knockout or non-target LoVo cells

Project description:Colorectal cancer (CRC) is one of the most common cancers and a major cause of cancer mortality worldwide. Further improvements are needed for the treatment of CRC. The E3 ubiquitin ligase is an enzyme that plays an important role in regulating protein expression levels via posttranslational ubiquitin-mediated proteolysis, and it is reportedly involved in the progression of various cancers, making it a target of recent interest in anticancer therapy. In this study, using comprehensive expression analysis involving spatial transcriptomic analysis with single-cell RNA sequencing in clinical CRC datasets, we identified the ubiquitin-associated protein Shank-associated RH domain interactor (SHARPIN) as a putative driver gene located on amplified chromosome 8q. SHARPIN was overexpressed in tumor cells, and high expression of SHARPIN in tumor tissues was positively correlated with lymphatic invasion and was independently predictive of a poor prognosis in CRC patients. In vitro and in vivo analyses using SHARPIN-overexpressing or -knockout CRC cells revealed that SHARPIN upregulated MDM2, resulting in subsequent downregulation of p53, which inhibits tumor cell apoptosis and promotes tumor growth in CRC. Furthermore, SHARPIN overexpression and significant effects on survival were observed in various cancers. In conclusion, SHARPIN is a novel driver gene that potentially promotes tumor growth following apoptosis inhibition in part by inhibiting p53 expression via MDM2 upregulation; therefore, SHARPIN represents a potential therapeutic target for CRC.

2024-02-14 | GSE255286 | GEO

microRNA array of LoVo cells and LoVo-Small Extracellular Vesicles

Project description:LoVo cells were cultured in sEV-depleted (160,000xg, 16h) complete medium and the supernatant were collected after 72h. sEVs were purified and centrifuged at 100,000xg for 2.5h using a Beckman SW41Ti rotor to know the miRNA in LoVo cells and LoVo-Small Extracellular Vesicles

2019-07-01 | GSE117866 | GEO

Next generation sequencing facilities quantitative analysis of ASAP2 knockout or wild-type Panc1 and MiaPaCa2 cells

Project description:Next generation sequencing facilities quantitative analysis of ASAP2 knockout or wild-type Panc1 and MiaPaCa2 cells

| PRJNA628186 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of si-nc and si-SRSF11 LOVO Transcriptomes

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of si-nc and si-SRSF11 LOVO Transcriptomes

| PRJNA818336 | ENA

Gene expression profiling in LoVo-P compared with LoVo-C cells

Project description:The differential expression of mRNA in LoVo-P cells compared with LoVo-C cells was successfully detected using the Arraystar Human LncRNA/mRNAArray V4.0, that used for the global profiling of 20730 human mRNA and 40173 long non-coding RNA (LncRNA) transcripts.

2017-09-20 | GSE103989 | GEO

Expression data from human colorectal cancer cell line LoVo

Project description:PEAK1 overexpression vector and negative control vector were transiently transfected into LoVo cells, respectively, and named LoVo-PEAK1 and LoVo-control groups. LoVo cells of different groups were determined to investigate the different expressions of mRNA using a global gene microarray.

2018-01-10 | GSE108947 | GEO

microRNA array of LoVo cells and LoVo-Small Extracellular Vesicles

Project description:microRNA array of LoVo cells and LoVo-Small Extracellular Vesicles

| PRJNA483459 | ENA

Transcriptomics of LoVo cells exposed to DCC-2036.

Project description:To investigate the mechanisms mediating the inhibitory effects of DCC-2036 on LoVo, gene expression profiling analysis using data obtained from RNA-seq of LoVo cells treated with/without DCC-2036.

2025-01-15 | GSE214063 | GEO

Expression data from Irinotecan resistant LoVo cells comapred to parental LoVo cells

Project description:Irinotecan, an analogue of camptothecin, is frequently used in combination with various anticancer drugs or as a single agent in treatment of colorectal cancer. But drug resistance of tumor is still a major obstacle to overcome for the success of cancer treatment. In this study, We established chronic irinotecan resistant cell line for new marker to increase the sensitivity to irinotecan and investigated gene expression profiles of the irinotecan-resistant colorectal cancer cell line. To create stable CRC cell line chronically resistant to Irinotecan, LoVo cell was exposed to an initial Irinotecan concentration of 0.1 M-NM-<mol/L in RPMI 1640 supplemented with 10% FBS. When the growth of the cultured cells reaches at 80% confluency, cells were passaged twice at same drug concentration to ensure adaptation and then concentration of Irinotecan was sequentially increased in the same manner to 8 M-NM-<mol/L and then we investigated the gene expressions between parental colorectal cancer cell line, LoVo and Irinotecan resistant LoVo cell lines

2014-07-18 | E-GEOD-59501 | biostudies-arrayexpress

Gene expression profiling in LoVo-P compared with LoVo-C cells

Project description:Gene expression profiling in LoVo-P compared with LoVo-C cells

| PRJNA407894 | ENA